Phase 2 clinical findings
A 48-week randomized study strengthened the clinical evidence for selective amylin-receptor signaling and supported progression into larger trials.
P—25 • Selective amylin development profile
Eloralintide(Also known as LY3841136)
An investigational long-acting selective amylin receptor agonist advancing through Phase 3 research as a standalone compound and alongside incretin therapy.
Name
Eloralintide
Also known as LY3841136
- Scientific classification
- Synthetic, long-acting selective amylin receptor agonist
- Library family
- Metabolic
- Regulatory status
- Investigational and not FDA approved
Compound overview
A selective amylin signal entering a broad late-stage research program.
Amylin is a naturally occurring peptide hormone released alongside insulin. It contributes to signals involving fullness, food intake, gastric activity, and metabolic regulation. Eloralintide was designed as a long-acting compound that selectively activates amylin receptors.
The evidence base has grown from an early proof-of-concept study into a 48-week randomized Phase 2 trial. That study reported dose-related body-weight changes across the groups studied and helped establish the rationale for a larger late-stage program.
In 2026, the ENLIGHTEN Phase 3 program began expanding the research into adults with obesity or overweight, including people with type 2 diabetes, obstructive sleep apnea, and persistent obesity while already receiving weekly incretin therapy.
A newly reported Phase 2b study also examined eloralintide together with tirzepatide. The investigational combination produced larger average changes in body weight and A1C than either medicine alone in the studied population, prompting plans for a Phase 3 combination program.
Eloralintide remains investigational. Larger trials must clarify its long-term safety, durability, role as a standalone compound, and whether combining amylin and incretin signaling adds meaningful benefits across different groups.
The ENLIGHTEN program
Phase 3 studies are now examining eloralintide across obesity, type 2 diabetes, sleep apnea, and persistent obesity during incretin treatment.
Combination research
New Phase 2b results are exploring whether pairing eloralintide with tirzepatide can build upon the effects of either approach alone.
Mechanism under study
Selective, long-acting amylin-receptor signaling
Eloralintide is being studied for sustained engagement of amylin receptors and the downstream metabolic responses associated with that pathway.
Amylin receptors
The compound is designed to selectively activate amylin receptors involved in satiety and metabolic signaling.
Long-acting exposure
Its molecular design is intended to support extended exposure, which is evaluated through pharmacokinetic studies.
Metabolic endpoints
Clinical research measures body weight, tolerability, and other metabolic outcomes under controlled study conditions.
Early clinical signals require confirmation in larger and longer trials. They do not establish an approved treatment or the equivalence of research-market materials.
Current research areas
Questions under investigation
- How amylin signaling affects fullness and food intake
- Long-term weight management
- Blood-sugar outcomes in people with type 2 diabetes
- Sleep apnea and other complications linked with obesity
- Using amylin therapy alongside established incretin medicines
Evidence summary
Encouraging clinical research signals
- Body-weight research: A 48-week Phase 2 study reported greater average body-weight reductions with eloralintide than placebo across the studied dose groups.
- Selective pathway: Eloralintide offers a way to study amylin-receptor signaling separately from GLP-1 and GIP pathways.
- Tolerability research: Early trials characterized adverse events and informed the dose-escalation approaches now being tested in larger studies.
- Combination potential: Phase 2b findings reported additional body-weight and A1C changes when eloralintide was studied with tirzepatide in adults with obesity or overweight and type 2 diabetes.
- Broader late-stage program: Phase 3 studies are testing whether early findings persist across larger, more varied populations and over longer periods.
Eloralintide and its combinations remain investigational. Early and mid-stage findings do not establish regulatory approval, long-term safety, or guaranteed individual outcomes.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, dosing information, or instructions for eloralintide use. Eloralintide is investigational, and published clinical material should not be assumed to match the identity, purity, or properties of research-market products.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.